Related Experiment Video

Updated: May 6, 2026

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

23.6K

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

Christian Rolfo1, Luis E Raez, Antonio Russo

  • 1Professor, Head of Phase I-Early Clinical Trials Unit, Antwerp University Hospital UZA, Oncology Department , Wilrijkstraat 10, 2650 Edegem , Belgium +32 3 821 36 46 ; christian.rolfo@uza.be.

Expert Opinion on Biological Therapy
|October 29, 2013
PubMed
Abstract

Insights

Denosumab is more effective than zoledronic acid in preventing skeletal-related events (SREs) in patients with bone metastasis from solid tumors. Denosumab delayed the first SRE by 17% compared to zoledronic acid.

Area of Science:

  • Oncology
  • Skeletal Metastasis Research

Background:

  • Bone metastases are a frequent complication of advanced solid tumors, causing significant pain and morbidity.
  • Skeletal-related events (SREs) are a major concern in patients with bone metastases.
  • Zoledronic acid is the current standard treatment for preventing SREs.

Purpose of the Study:

  • To review clinical trials comparing the efficacy of denosumab and zoledronic acid in preventing SREs.
  • To evaluate denosumab's superiority over zoledronic acid in managing bone metastases.

Main Methods:

  • Systematic review of clinical trials.
  • Comparison of denosumab versus zoledronic acid efficacy in patients with osteotropic tumors.
  • Analysis of time to first SRE as a primary endpoint.

Main Results:

  • Denosumab demonstrated superior efficacy in preventing or delaying SREs compared to zoledronic acid.
  • Denosumab significantly delayed the time to the first SRE by 17% in patients with bone metastases.
  • The study focused on patients with solid tumors metastasizing to the bone.

Conclusions:

  • Denosumab is a more effective treatment option than zoledronic acid for preventing SREs in patients with bone metastases.
  • Ongoing research is exploring denosumab's potential immunomodulatory and antitumor effects.

More Related Videos

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.4K
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
34.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K